EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone After Resection of Gallbladder Carcinoma: A Real-World, Inverse Probability of Treatment Weighting-Based Cohort Study

Qiuyi Zheng, Bei Lv, Yixing Chen, Shujung Hsu, Yang Zhang, Siwei Wang, Houbao Liu, Tao Suo, Zhaochong Zeng, Shisuo Du

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.09.023 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Qiuyi Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Gallbladder Neoplasms, Chemoradiotherapy, Adjuvant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Shanghai Anti-Cancer Association, Zhongshan Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare overall survival (OS) and disease-free survival (DFS) in patients with advanced resectable gallbladder carcinoma (GBC) receiving radical resection followed by chemoradiation therapy (S+CRT) or chemotherapy alone (S+CT). METHODS AND MATERIALS: This real-world study included 239 patients (pT2-4, N0-2, M0) treated between February 2017 and November 2021. Inverse probability of treatment weighting (IPTW) was applied to balance baseline variables between S+CRT and S+CT groups. Kaplan-Meier analysis and Cox regression were used to evaluate survival. Predefined subgroups analyses were conducted for 77 patients with incidental GBC and 94 patients with nodal metastasis (pN+). Adverse events and recurrence patterns were recorded for the entire cohort. RESULTS: Median follow-up was 57.4 months. IPTW created 472.6 weighted patients with well-balanced characteristics. S+CRT was associated with higher OS and DFS at 1, 3, and 5 years compared with S+CT (OS, 90.5%, 71.9%, 65.8% vs 81.6%, 56.1%, 50.1%; DFS, 77.8%, 65.1%, 57.7% vs 63.1%, 45.3%, 42.6%). Median OS and DFS were not reached in the S+CRT group. In the incidental GBC subgroup, survival differences were not statistically significant overall, but a landmark analysis beyond 24 months revealed improved OS favoring S+CRT (P = .011). Similarly, in the subgroup with nodal metastasis (pN+), adjuvant CRT was associated with a significant improvement in DFS. CONCLUSIONS: Postoperative CRT significantly improved OS and DFS in balanced patients with stage II-IV GBC. A delayed OS benefit was observed in patients with incidental GBC, whereas patients with nodal metastasis also experienced significantly improved DFS. Although intrahepatic recurrence remained predominant, CRT notably reduced local failures without significantly increasing treatment-related toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallbladder NeoplasmsChemoradiotherapy, AdjuvantHumansMaleFemaleMiddle AgedAgedDisease-Free SurvivalCohort StudiesAdultLymphatic MetastasisRetrospective StudiesAged, 80 and overProbabilityChemotherapy, Adjuvant

Autor:innen und Institutionen

  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Zhongshan Hospital, Liver Cancer Institute, Fudan Uni…
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Biliary Surgery, Biliary Tract Disease Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: du.shisuo@zs-hospital.sh.cn.

Förderung

  • Shanghai Anti-Cancer Association
  • Zhongshan Hospital
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Zheng, Q., Lv, B., Chen, Y., Hsu, S., Zhang, Y., Wang, S., Liu, H., Suo, T., Zeng, Z., & Du, S. (2026). Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone After Resection of Gallbladder Carcinoma: A Real-World, Inverse Probability of Treatment Weighting-Based Cohort Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.09.023

Vancouver

Zheng Q, Lv B, Chen Y, Hsu S, Zhang Y, Wang S, et al. Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone After Resection of Gallbladder Carcinoma: A Real-World, Inverse Probability of Treatment Weighting-Based Cohort Study. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.09.023

BibTeX
@article{Zheng2026,
  author = {Zheng, Qiuyi and Lv, Bei and Chen, Yixing and Hsu, Shujung and Zhang, Yang and Wang, Siwei and Liu, Houbao and Suo, Tao and Zeng, Zhaochong and Du, Shisuo},
  title = {Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone After Resection of Gallbladder Carcinoma: A Real-World, Inverse Probability of Treatment Weighting-Based Cohort Study},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.09.023}
}
Kostenlos starten →